FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367019033> ?p ?o ?g. }

• W4367019033 endingPage "e46157" @default.
• W4367019033 startingPage "e46157" @default.
• W4367019033 abstract "Bipolar disorder (BD) is a highly prevalent psychiatric condition that can significantly impact every aspect of a person's life if left untreated. A subtype of BD, bipolar disorder type II (BD-II), is characterized by long depressive episodes and residual depression symptoms, with short-lived hypomanic episodes. Medication and psychotherapy, such as cognitive behavioral therapy (CBT), are the main treatment options for BD-II. CBT specific for BD-II involves the recognition of warning signs, potentially triggering stimuli, and the development of coping skills to increase euthymic periods and improve global functioning. However, access to in-person CBT may be limited by several barriers, including low availability, high costs, and geographical limitations. Thus, web-based adaptations of CBT (e-CBT) have become a promising solution to address these treatment barriers. Nevertheless, e-CBT for the treatment of BD-II remains understudied.The proposed study aims to establish the first e-CBT program specific for the treatment of BD-II with residual depressive symptoms. The primary objective of this study will be to determine the effect of e-CBT in managing BD symptomatology. The secondary objective will be to assess the effects of this e-CBT program on quality of life and resilience. The tertiary objective will involve gathering user feedback using a posttreatment survey to support the continuous improvement and optimization of the proposed program.Adult participants (N=170) with a confirmed diagnosis of BD-II experiencing residual depressive symptoms will be randomly assigned to either the e-CBT and treatment as usual (TAU; n=85) group or the TAU (n=85) control group. Participants in the control group will be able to participate in the web-based program after the first 13 weeks. The e-CBT program will consist of 13 weekly web-based modules designed following a validated CBT framework. Participants will complete module-related homework and receive asynchronous personalized feedback from a therapist. TAU will consist of standard treatment services conducted outside of this research study. Depression and manic symptoms, quality of life, and resiliency will be assessed using clinically validated symptomatology questionnaires at baseline, week 6, and week 13.The study received ethics approval in March 2020, and participant recruitment is expected to begin in February 2023 through targeted advertisements and physician referrals. Data collection and analysis are expected to conclude by December 2024. Linear and binomial regression (continuous and categorical outcomes, respectively) will be conducted along with qualitative interpretive methods.The findings will be the first on the effectiveness of delivering e-CBT for patients with BD-II with residual depressive symptoms. This approach can provide an innovative method to address barriers to in-person psychotherapy by increasing accessibility and decreasing costs.ClinicalTrials.gov NCT04664257; https://clinicaltrials.gov/ct2/show/NCT04664257.PRR1-10.2196/46157." @default.
• W4367019033 created "2023-04-27" @default.
• W4367019033 creator A5012811032 @default.
• W4367019033 creator A5015434278 @default.
• W4367019033 creator A5040971877 @default.
• W4367019033 creator A5048744582 @default.
• W4367019033 creator A5050616402 @default.
• W4367019033 creator A5060281456 @default.
• W4367019033 creator A5062242930 @default.
• W4367019033 creator A5065802251 @default.
• W4367019033 creator A5079550920 @default.
• W4367019033 creator A5079688435 @default.
• W4367019033 creator A5081543422 @default.
• W4367019033 date "2023-05-19" @default.
• W4367019033 modified "2023-10-18" @default.
• W4367019033 title "Evaluating the Efficacy of Web-Based Cognitive Behavioral Therapy for the Treatment of Patients With Bipolar II Disorder and Residual Depressive Symptoms: Protocol for a Randomized Controlled Trial" @default.
• W4367019033 cites W1525840829 @default.
• W4367019033 cites W1598260793 @default.
• W4367019033 cites W1674684315 @default.
• W4367019033 cites W1906922166 @default.
• W4367019033 cites W1968125439 @default.
• W4367019033 cites W1981653794 @default.
• W4367019033 cites W1984216694 @default.
• W4367019033 cites W1992599216 @default.
• W4367019033 cites W2021602762 @default.
• W4367019033 cites W2034792075 @default.
• W4367019033 cites W2055778732 @default.
• W4367019033 cites W2057535464 @default.
• W4367019033 cites W2062192811 @default.
• W4367019033 cites W2075286650 @default.
• W4367019033 cites W2085660025 @default.
• W4367019033 cites W2087745459 @default.
• W4367019033 cites W2111424037 @default.
• W4367019033 cites W2118826874 @default.
• W4367019033 cites W2122677855 @default.
• W4367019033 cites W2128900442 @default.
• W4367019033 cites W2147310811 @default.
• W4367019033 cites W2160263787 @default.
• W4367019033 cites W2164547019 @default.
• W4367019033 cites W2168941781 @default.
• W4367019033 cites W2269399764 @default.
• W4367019033 cites W2413281205 @default.
• W4367019033 cites W2563770163 @default.
• W4367019033 cites W2809509324 @default.
• W4367019033 cites W2884313467 @default.
• W4367019033 cites W2950709739 @default.
• W4367019033 cites W2960566636 @default.
• W4367019033 cites W2979817204 @default.
• W4367019033 cites W3000431195 @default.
• W4367019033 cites W3012534542 @default.
• W4367019033 cites W3107882356 @default.
• W4367019033 cites W3131680759 @default.
• W4367019033 cites W3135445184 @default.
• W4367019033 cites W3171418018 @default.
• W4367019033 cites W4235636163 @default.
• W4367019033 cites W4237330839 @default.
• W4367019033 doi "https://doi.org/10.2196/46157" @default.
• W4367019033 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37140460" @default.
• W4367019033 hasPublicationYear "2023" @default.
• W4367019033 type Work @default.
• W4367019033 citedByCount "0" @default.
• W4367019033 crossrefType "journal-article" @default.
• W4367019033 hasAuthorship W4367019033A5012811032 @default.
• W4367019033 hasAuthorship W4367019033A5015434278 @default.
• W4367019033 hasAuthorship W4367019033A5040971877 @default.
• W4367019033 hasAuthorship W4367019033A5048744582 @default.
• W4367019033 hasAuthorship W4367019033A5050616402 @default.
• W4367019033 hasAuthorship W4367019033A5060281456 @default.
• W4367019033 hasAuthorship W4367019033A5062242930 @default.
• W4367019033 hasAuthorship W4367019033A5065802251 @default.
• W4367019033 hasAuthorship W4367019033A5079550920 @default.
• W4367019033 hasAuthorship W4367019033A5079688435 @default.
• W4367019033 hasAuthorship W4367019033A5081543422 @default.
• W4367019033 hasBestOaLocation W43670190331 @default.
• W4367019033 hasConcept C118552586 @default.
• W4367019033 hasConcept C126322002 @default.
• W4367019033 hasConcept C15744967 @default.
• W4367019033 hasConcept C168563851 @default.
• W4367019033 hasConcept C169900460 @default.
• W4367019033 hasConcept C2776174506 @default.
• W4367019033 hasConcept C2779477915 @default.
• W4367019033 hasConcept C2779951463 @default.
• W4367019033 hasConcept C2780051608 @default.
• W4367019033 hasConcept C2781265626 @default.
• W4367019033 hasConcept C542102704 @default.
• W4367019033 hasConcept C70410870 @default.
• W4367019033 hasConcept C71924100 @default.
• W4367019033 hasConcept C73282008 @default.
• W4367019033 hasConceptScore W4367019033C118552586 @default.
• W4367019033 hasConceptScore W4367019033C126322002 @default.
• W4367019033 hasConceptScore W4367019033C15744967 @default.
• W4367019033 hasConceptScore W4367019033C168563851 @default.
• W4367019033 hasConceptScore W4367019033C169900460 @default.
• W4367019033 hasConceptScore W4367019033C2776174506 @default.
• W4367019033 hasConceptScore W4367019033C2779477915 @default.
• W4367019033 hasConceptScore W4367019033C2779951463 @default.
• W4367019033 hasConceptScore W4367019033C2780051608 @default.
• W4367019033 hasConceptScore W4367019033C2781265626 @default.

• next